Here is the standalone HTML5 article block:
BERLIN — Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed to treat type 2 diabetes, have revolutionized obesity care in recent years. Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are now widely prescribed for weight management, with millions of patients worldwide reporting significant health improvements. But emerging research suggests these drugs may offer benefits far beyond blood sugar control and weight loss, potentially transforming treatment for a range of chronic and complex conditions.
As a physician and health journalist with more than a decade of experience in internal medicine and medical reporting, I’ve followed the rapid evolution of GLP-1 therapies closely. What began as a diabetes treatment has now expanded into a multi-billion-dollar industry, with pharmaceutical companies racing to explore new applications. The U.S. Food and Drug Administration (FDA) has already approved some GLP-1 drugs for additional conditions, including heart disease, chronic kidney disease, and advanced liver disease. Meanwhile, researchers are investigating their potential in areas as diverse as addiction, autoimmune disorders, and even cancer prevention.
The broad therapeutic potential of GLP-1 drugs stems from their ability to target fundamental biological processes. These medications work by mimicking the action of the natural hormone GLP-1, which plays a key role in regulating blood sugar, appetite, and metabolism. But GLP-1 receptors are found throughout the body, including in the brain, heart, kidneys, and immune system. This widespread distribution helps explain why these drugs may influence such a wide range of health conditions, from inflammatory diseases to neurological disorders.
From Diabetes to Heart Disease: The Expanding FDA Approvals
The first GLP-1 receptor agonist, exenatide (Byetta), was approved for type 2 diabetes in 2005. Since then, the class has grown to include several blockbuster drugs, with semaglutide and tirzepatide leading the way. While these medications were initially developed to improve glycemic control, their weight-loss effects quickly became apparent. In 2014, liraglutide (Saxenda) became the first GLP-1 drug approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
The therapeutic landscape shifted dramatically in 2024, when the FDA approved Wegovy (semaglutide) for reducing the risk of major cardiovascular events in adults with established heart disease who are overweight or obese. This marked the first time a GLP-1 drug received approval for a condition unrelated to diabetes or obesity. The decision was based on results from the SELECT trial, a large randomized study involving more than 17,000 participants. The trial found that Wegovy reduced the risk of heart attack, stroke, or cardiovascular death by 20% compared to placebo, even though participants lost only about 8-9% of their body weight on average (New England Journal of Medicine, 2023).
“This indicates that there are mechanisms that go well beyond just weight loss or glucose lowering,” said Dr. Jamy Ard, a professor of epidemiology and prevention at Wake Forest University School of Medicine, in an interview with the American Heart Association. The SELECT trial was the first large, randomized study to reveal that a drug used for obesity could reduce cardiovascular disease, challenging long-held perceptions of obesity as primarily a cosmetic concern rather than a medical risk factor (American Heart Association, 2023).
In December 2024, the FDA approved Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This was the first medication approved specifically for sleep apnea, a condition in which people repeatedly stop breathing during sleep, often due to excess weight pressing on the airway. Clinical trials showed that Zepbound reduced the number of breathing interruptions per hour by up to 63% in some patients, alongside significant weight loss (FDA, 2024).
Most recently, in August 2025, the FDA approved Wegovy for the treatment of metabolic-associated steatohepatitis (MASH), a severe form of fatty liver disease that can lead to cirrhosis and liver failure. The approval was based on results from the ESSENCE trial, a phase 3 study involving 1,200 adults with MASH and moderate to advanced liver fibrosis. Participants who received semaglutide showed significant improvements in liver inflammation and fibrosis compared to placebo, as confirmed by liver biopsies (New England Journal of Medicine, 2025).
Beyond Approved Uses: Conditions Under Investigation
While the FDA has expanded the approved uses of GLP-1 drugs, researchers are exploring their potential in a growing number of other conditions. As of mid-2025, there are more than 400 active clinical trials investigating GLP-1 therapies for a wide range of diseases, according to the U.S. National Library of Medicine’s ClinicalTrials.gov database. Here’s a look at some of the most promising areas of research:
Autoimmune and Inflammatory Diseases
Obesity is a known risk factor for several autoimmune conditions, including psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Excess weight can exacerbate inflammation and reduce the effectiveness of treatments. A 36-week clinical trial published in 2024 investigated the combined use of the PsA biologic drug ixekizumab (Taltz) with the GLP-1 drug tirzepatide (Zepbound) in adults with active PsA and overweight or obesity. The study found that nearly 32% of participants achieved a 50% improvement in PsA activity, alongside a weight reduction of at least 10%. Side effects were mild to moderate, but researchers noted that longer-term studies are needed to assess the durability of these benefits (Annals of the Rheumatic Diseases, 2024).
For rheumatoid arthritis, a retrospective chart review found that patients with RA who were also taking GLP-1 drugs experienced greater improvements in disease activity and pain, as well as better cardiometabolic markers like weight, cholesterol, and blood sugar levels, compared to similar patients not taking a GLP-1. While these findings are preliminary, they suggest that GLP-1 therapies may offer additional benefits for people with RA who are overweight or obese (Arthritis Research & Therapy, 2023).
Polycystic Ovary Syndrome (PCOS)
Polycystic ovary syndrome (PCOS) is a hormonal disorder that affects up to 10% of women of reproductive age. It is characterized by elevated testosterone levels, insulin resistance, and metabolic complications, often leading to infertility, irregular periods, and weight gain. Several studies have shown that GLP-1 drugs, sometimes combined with metformin, can help women with PCOS lose weight and improve insulin sensitivity. Some research has also found improvements in ovulation and pregnancy rates, though GLP-1 drugs are not recommended for women who are pregnant or trying to conceive (Journal of Clinical Endocrinology & Metabolism, 2022).
Addiction and Substance Use Disorders
One of the most intriguing areas of research involves the potential of GLP-1 drugs to treat addiction. Soon after these medications became widely used for diabetes and weight loss, users began reporting fewer cravings for alcohol, cigarettes, and even compulsive behaviors like gambling. “This is thought to be related to GLP-1s’ effects on the brain’s dopamine reward pathway,” said Dr. Nitya Kumar, an endocrinologist and assistant professor of medicine at Duke University School of Medicine.
A large Swedish study published in 2024 found that people taking semaglutide or liraglutide had fewer hospitalizations for alcohol use disorder compared to periods when they were not taking the drugs. More recently, a nine-week randomized trial published in 2025 showed that semaglutide reduced alcohol cravings and intake, and in a subgroup of participants, it also reduced cigarette smoking. While these findings are promising, GLP-1 drugs are not yet FDA-approved for addiction treatment, and more research is needed to understand their long-term effects (JAMA Internal Medicine, 2024).
Cancer Prevention
Obesity is a well-established risk factor for several types of cancer, including colorectal, breast, and liver cancer. Observational studies have suggested that people with obesity who take GLP-1 drugs may have a lower risk of developing certain obesity-related cancers compared to those who do not take these medications. Colorectal cancer, in particular, has shown the most promise in this area. Although, experts caution that these studies are observational and cannot prove causation. The potential protective effects may be related to weight loss, improved metabolism, and reduced inflammation, but more research is needed (National Cancer Institute, 2024).
Why GLP-1 Drugs May Have Such Broad Effects
The wide-ranging therapeutic potential of GLP-1 drugs can be traced to their ability to target multiple biological pathways. While these medications were initially designed to regulate insulin and glucagon in the pancreas, GLP-1 receptors are found in many other parts of the body, including the brain, cardiovascular system, immune system, gut, and kidneys. This widespread distribution allows GLP-1 drugs to influence a variety of physiological processes beyond glucose metabolism and appetite control.
“I believe these medications have such broad effects because a lot of health problems begin with disruptions in insulin resistance and inflammation,” said Dr. Ard. “The combination of insulin resistance and inflammation creates an overwhelming biological effect. There is no organ system that is not affected by this internal metabolic environment.”
GLP-1 drugs are highly effective at reducing calorie intake, which can directly improve insulin sensitivity and glucose metabolism. They also appear to have anti-inflammatory effects, though it remains unclear whether this is a direct result of the drugs or an indirect effect of weight loss. Diana Isaacs, an endocrine clinical pharmacy specialist at the Cleveland Clinic, noted that the presence of GLP-1 receptors in multiple organ systems makes these drugs promising candidates for treating a variety of conditions. “Researchers have observed the drugs’ impact on diseases other than diabetes and obesity in clinical trials, as well as in people taking the medications in the real world,” she said (Cleveland Clinic, 2025).
Challenges and Considerations
Despite their promise, GLP-1 drugs are not without challenges. Cost remains a significant barrier, with list prices for these medications often exceeding $1,000 per month. While some insurance plans cover GLP-1 drugs for diabetes or obesity, coverage for other conditions is less consistent. The recent FDA approvals for heart disease and sleep apnea may help expand insurance coverage, but access remains a concern for many patients.
Side effects are another consideration. The most common side effects of GLP-1 drugs include nausea, vomiting, diarrhea, and constipation, though these often improve over time. More serious but rare side effects can include pancreatitis, gallbladder disease, and an increased risk of thyroid tumors. Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 are advised not to take these medications.
There are also questions about the long-term effects of GLP-1 drugs, particularly for conditions that are still under investigation. For example, while early research suggests these drugs may help reduce alcohol cravings, it is unclear whether these effects will persist over time or whether patients will experience rebound cravings after stopping the medication. Similarly, the potential cancer-preventive effects of GLP-1 drugs require further study in large, randomized trials.
What’s Next for GLP-1 Research?
The next few years are likely to bring significant advances in our understanding of GLP-1 drugs. Several large clinical trials are currently underway to explore their potential in conditions like Alzheimer’s disease, Parkinson’s disease, and non-alcoholic fatty liver disease. Pharmaceutical companies are also developing new GLP-1-based therapies with improved efficacy and fewer side effects.
One area of particular interest is the development of oral GLP-1 drugs. While most GLP-1 medications are currently administered via injection, oral formulations of semaglutide have already been approved for diabetes and are being studied for other conditions. These oral versions could improve patient adherence and expand access to GLP-1 therapies.
For patients and healthcare providers, the expanding role of GLP-1 drugs offers new hope for managing complex and often interconnected health conditions. As research continues to uncover the full potential of these medications, they may well redefine the treatment landscape for obesity and its related complications.
Key Takeaways
- FDA-Approved Uses: GLP-1 drugs are currently approved for type 2 diabetes, obesity, heart disease in people with overweight or obesity, chronic kidney disease in people with obesity and diabetes, metabolic-associated steatohepatitis (MASH), and obstructive sleep apnea in adults with obesity.
- Broad Therapeutic Potential: Researchers are investigating GLP-1 drugs for a wide range of conditions, including autoimmune diseases, polycystic ovary syndrome (PCOS), addiction, cancer prevention, and neurodegenerative disorders.
- Mechanism of Action: GLP-1 drugs work by mimicking the natural hormone GLP-1, which regulates blood sugar, appetite, and metabolism. Their broad effects are likely due to the widespread distribution of GLP-1 receptors throughout the body.
- Challenges: Cost, side effects, and long-term safety are key considerations. Access to these medications remains limited for many patients, though recent FDA approvals may help expand insurance coverage.
- Future Research: Ongoing clinical trials are exploring new applications for GLP-1 drugs, including oral formulations and potential treatments for Alzheimer’s disease and Parkinson’s disease.
The next major milestone in GLP-1 research is expected later this year, with the publication of results from several large clinical trials investigating these drugs for liver disease, kidney disease, and neurological conditions. Patients and providers can stay updated on the latest developments through the ClinicalTrials.gov database and official FDA announcements.
As a physician and health journalist, I’m continually amazed by the rapid pace of innovation in this field. What began as a diabetes treatment has now opened new avenues for addressing some of the most challenging and interconnected health conditions of our time. Have you or someone you know experienced benefits from GLP-1 drugs beyond weight loss or diabetes management? Share your story in the comments below, and let’s continue the conversation.